Search for new products by date added, alphabetically, or by pharmacological action.
New products are an essential component of our range. Introductions are made on an ongoing basis, with hundreds of new small molecules and peptides being added every year. Our aim is to find the latest, otherwise unobtainable research tools, and bring them to the market as quickly as we can. New products can be identified throughout the Tocris website by the New symbol.
If you can't find what you are looking for we welcome new product suggestions. If you would like to be kept informed about new products by email, please sign up for our monthly e-alert service.
| Cat No | Product Name / Activity | Date Added |
|---|---|---|
| 6774 | 16673-34-0 NLRP3i | Jan 2019 |
| NLRP3 inflammasome inhibitor | ||
| 6802 | 6 TMR Tre | Feb 2019 |
| Fluorescent trehalose; selectively labels mycobacterial cell envelope | ||
| 6868 | 8-Azaadenosine | May 2019 |
| ADAR1 (adenosine deaminases acting on double-stranded RNA) inhibitor; inhibits leukemia stem cell self-renewal | ||
| 6470 | A 410099.1 | Feb 2019 |
| High affinity XIAP antagonist; active in vivo | ||
| 6715 | A 71915 | Jan 2019 |
| Highly potent and competitive NPRA antagonist | ||
| 6712 | A 77-01 | Dec 2018 |
| Potent inhibitor of TGF-βRI | ||
| 6759 | AA 147 | Feb 2019 |
| ER proteostasis regulator | ||
| 6770 | ABT 639 | Mar 2019 |
| CaV3.2 and CaV3.1 channel blocker; orally bioavailable | ||
| 6766 | AC 1903 | Mar 2019 |
| Selective TRPC5 blocker | ||
| 6840 | AD 01 | May 2019 |
| FKBPL (FK506-binding protein like)-based peptide; inhibits breast cancer stem cell self-renewal; also antiangiogenic | ||
| 5862 | ARN 14686 | Apr 2019 |
| Potent N-acylethanolamine acid amidase inhibitor; NAAA activity-based protein profiling (ABPP) probe | ||
| 6763 | AVE 1625 | Apr 2019 |
| Potent and selective CB1 receptor antagonist | ||
| 6177 | AZ 13705339 | Dec 2018 |
| Highly potent PAK1 and PAK2 inhibitor | ||
| 6806 | AZ 3451 | Apr 2019 |
| Potent negative allosteric modulator of PAR2 | ||
| 6541 | AZD 2098 | Jan 2019 |
| Potent and selective CCR4 antagonist | ||
| 6742 | Acetazolamide | Dec 2018 |
| Carbonic anhydrase inhibitor | ||
| 6812 | Afatinib dimaleate | Mar 2019 |
| Potent dual specificity EGFR/HER2 inhibitor; active in vivo | ||
| 6818 | Artemether | Mar 2019 |
| Antimalarial; also inhibits neuroinflammation | ||
| 6827 | Artesunate | Mar 2019 |
| Suppresses ROS-induced activation of the NLRP3 inflammasome; antimalarial | ||
| 6834 | Auxin | Mar 2019 |
| Chemical dimerizer used in auxin-inducible degron (AID) system; phytohormone | ||
| 6579 | BAY 826 | Dec 2018 |
| Potent Tie2 inhibitor | ||
| 6246 | BF 738735 | Apr 2019 |
| Potent and selective PI 4-kinase IIIβ inhibitor; broad spectrum enterovirus replication inhibitor | ||
| 6518 | BI 01383298 | Feb 2019 |
| Potent and selective SLC13A5 (Na+/citrate cotransporter) inhibitor | ||
| 1304 | BW-B 70C | Mar 2019 |
| 5-Lipoxygenase inhibitor | ||
| 6786 | BzF | Feb 2019 |
| Photoreactive unnatural amino acid | ||
| 6724 | CBA | Feb 2019 |
| Selective TRPM4 blocker | ||
| 6695 | CHIR 98014 | Feb 2019 |
| Highly potent and selective GSK-3 inhibitor | ||
| TB4423-GMP | CHIR 99021 | Dec 2018 |
| CHIR 99021 synthesized to cGMP guidelines | ||
| 6753 | CHS 828 | Mar 2019 |
| NAMPT inhibitor; active in vivo and cytotoxic | ||
| 6690 | Ceralifimod | May 2019 |
| Highly potent and selective S1P1 and S1P5 agonist | ||
| 6702 | Cerulenin | Feb 2019 |
| Irreversible fatty acid synthase inhibitor | ||
| 6798 | Click N-Acetylmuramic acid - alkyne | Feb 2019 |
| Bacterial peptidoglycan derivative; suitable for 'click'-conjugation to fluorescent dyes | ||
| 6830 | Conivaptan hydrochloride | Mar 2019 |
| Very high affinity vasopressin V1A and V2 antagonist; orally bioavailable | ||
| 6582 | D-3 | Dec 2018 |
| Selective PSC eliminating agent | ||
| 6434 | DFHO | Apr 2019 |
| Mimic of RFP fluorophore for imaging RNA in living cells | ||
| 6706 | DPNB-ABT 594 | Mar 2019 |
| Caged ABT 594; suitable for one- or two-photon photolysis | ||
| 6755 | Darapladib | Mar 2019 |
| Potent lp-PLA2 inhibitor | ||
| 6710 | Darunavir | Dec 2018 |
| Highly potent HIV protease inhibitor | ||
| 6793 | Dasatinib | Feb 2019 |
| Highly potent pan-Src/Bcr-Abl inhibitor | ||
| 6882 | DiFMUP | May 2019 |
| Fluorescent phophatase substrate | ||
| 6705 | Diminazene aceturate | Feb 2019 |
| ASIC blocker; antihyperalgesic | ||
| 6785 | E 7820 | Apr 2019 |
| α2 integrin inhibitor; anti-angiogenic | ||
| 6698 | ELA-11 (human) | Jan 2019 |
| High affinity apelin agonist | ||
| 6697 | ELA-21 (human) | Jan 2019 |
| High affinity apelin agonist | ||
| 6832 | Ec2la | May 2019 |
| CB2 receptor positive allosteric modulator; active in vivo | ||
| 6340 | Epiblastin A | Jan 2019 |
| CK1 inhibitor; converts epiblast stem cells to ESCs and promotes ESC self-renewal | ||
| 6717 | FFN 270 | May 2019 |
| Fluorescent substrate for NET and VMAT2 | ||
| 6653 | FM19G11 | Feb 2019 |
| HIF α-subunit inhibitor | ||
| 6784 | FTBMT | Mar 2019 |
| Potent and selective GPR52 agonist; orally bioavailable and BBB permeable | ||
| 6689 | GI 530159 | Jan 2019 |
| TREK1 and TREK2 channel activator | ||
| 6699 | [D-Ala2]-GIP (human) | Jan 2019 |
| Highly potent GIP agonist | ||
| 6490 | GNE 2861 | Mar 2019 |
| Group II PAK inhibitor; potently inhibits PAK4 and PAK 6 | ||
| 6369 | GNE 9278 | Jan 2019 |
| Positive allosteric modulator of NMDA receptors; acts in transmembrane domain | ||
| 6362 | GSK 143 | May 2019 |
| Syk inhibitor | ||
| 6709 | GSK 2018682 | Jan 2019 |
| S1P1 and S1P5 agonist | ||
| 6935 | GSK J5 HCl | May 2019 |
| Inactive isomer of GSK J4 (Cat. No. 4594); cell permeable | ||
| 6676 | IC 261 | Dec 2018 |
| CK1 inhibitor; displays selectivity for CK1δ and CK1ε | ||
| 6813 | Ibrutinib | Apr 2019 |
| Potent and selective BTK inhibitor | ||
| 6704 | Indo 1AM | Nov 2018 |
| Fluorescent Ca2+ indicator | ||
| 6553 | JF-NP-26 | Jan 2019 |
| Caged Raseglurant (Cat. No. 4416) | ||
| 6378 | JMS 17-2 hydrochloride | Apr 2019 |
| CX3CR1 antagonist | ||
| 6439 | JNJ 0966 | Mar 2019 |
| Pro-MMP9 activation inhibitor | ||
| 6279 | JNJ 39758979 dihydrochloride | Dec 2018 |
| High affinity and selective histamine H4 receptor antagonist; orally bioavailable | ||
| 6502 | Janelia Fluor® 549, Tetrazine | Apr 2019 |
| Cell permeable yellow fluorescent dye; supplied as a tetrazine for 'click' chemistry | ||
| 6590 | Janelia Fluor® 646, Maleimide | Dec 2018 |
| Red fluorescent dye, supplied with a maleimide reactive group | ||
| 6787 | KI-7 | Mar 2019 |
| A2B receptor positive allosteric modulator | ||
| 6272 | KYP 2047 | Mar 2019 |
| High affinity prolyl oligopeptidase inhibitor; anti-angiogenic, neuroprotective and brain penetrant | ||
| 5026 | KYT 0353 | May 2019 |
| Potent and selective inhibitor of L-type amino acid transporter 1 (LAT1); active in vivo | ||
| 6664 | Kinesore | Mar 2019 |
| Kinesin-1 modulator; cell permeable | ||
| 6644 | KuWal151 | Jan 2019 |
| Potent and selective CLK inhibitor | ||
| 6809 | L-DON | Feb 2019 |
| Glutaminase inhibitor; also inhibits other glutamine-using enzymes and transporters | ||
| 6752 | LDC 000067 | Mar 2019 |
| Potent and selective CDK9 inhibitor | ||
| 6754 | LJI308 | Mar 2019 |
| Potent pan-RSK inhibitor | ||
| 6510 | LNT 1 | Apr 2019 |
| Potent flap endonuclease 1 (FEN1) inhibitor; induces DNA damage response | ||
| 5496 | LP 99 | Dec 2018 |
| Selective BRD7 and BRD9 inhibitor | ||
| 5984 | LY 2955303 | Jan 2019 |
| High affinity and selective RARγ antagonist | ||
| 6811 | Lapatinib | Apr 2019 |
| Potent and selective dual ErbB2 (HER-2) and EGFR inhibitor | ||
| 6618 | MB 05032 | Dec 2018 |
| Potent FBPase inhibitor; promotes HSC expansion | ||
| 6668 | ML 184 | Jan 2019 |
| Selective GPR55 agonist; also promotes NSC proliferation and differentiation | ||
| 6429 | ML 210 | Mar 2019 |
| Selectively kills mutant HRAS-expressing cells; glutathione peroxidase inhibitor; induces ferroptosis | ||
| 6243 | ML 385 | Jan 2019 |
| Nrf2 inhibitor; phenotypically lethal | ||
| 6856 | α-Mangostin | Apr 2019 |
| Inhibits proliferation and induces apoptosis selectively in pancreatic CSCs and cancer cell lines | ||
| 6819 | Mefloquine hydrochloride | Mar 2019 |
| Cx36 and Cx50 gap channel blocker; also antimalarial and antischistosomal | ||
| 6652 | NGI 1 | Dec 2018 |
| Oligosaccharyltransferase (OST) inhibitor; anti-flaviviral | ||
| 6535 | NVP 2 | Feb 2019 |
| Potent and selective ATP-competitive CDK9 inhibitor | ||
| 6598 | OD 36 hydrochloride | Jan 2019 |
| Potent RIP2 kinase inhibitor | ||
| 6792 | Omipalisib | May 2019 |
| Highly potent PI 3-kinase inhibitor; also potent inhibitor of mTOR and DNA-PK | ||
| 6771 | PHPS1 sodium salt | May 2019 |
| Shp2 (PTPN11) inhibitor | ||
| 6748 | PRX 07034 | Apr 2019 |
| Potent and selective 5-HT6 antagonist | ||
| 6451 | Pexacerfont | Apr 2019 |
| Potent and selective CRF1 antagonist; anxiolytic | ||
| 5782 | Phalloidin-FITC | Dec 2018 |
| Green fluorescent cytoskeleton stain | ||
| 6622 | Phalloidin-TFAX 488 | Dec 2018 |
| Green fluorescent cytoskeletal stain; binds F-actin | ||
| 5783 | Phalloidin-TRITC | Dec 2018 |
| Red-orange fluorescent cytoskeleton stain | ||
| 6681 | Pomalidomide - linker 2 | Jan 2019 |
| Pomalidomide-PEG3-carboxylic acid | ||
| 6682 | Pomalidomide - linker 3 | Jan 2019 |
| Pomalidomide-alkylC5-carboxylic acid | ||
| 6851 | Pomalidomide - linker 7 | Mar 2019 |
| Pomalidomide-alkylC2-amine | ||
| 6577 | Pyridone 6 | Feb 2019 |
| Potent pan-JAK inhibitor; induces intermediate mesoderm; cell-permeable | ||
| 6788 | Quizartinib | Jan 2019 |
| Highly potent FLT3 inhibitor | ||
| 6530 | R 121919 hydrochloride | Dec 2018 |
| High affinity CRF1 antagonist; orally bioavailable | ||
| 6845 | RCM 1 | May 2019 |
| FOXM1 inhibitor | ||
| 6728 | RGFP 966 | Mar 2019 |
| Potent and selective HDAC3 inhibitor | ||
| 6567 | RI-STAD 2 | Feb 2019 |
| AKAP disruptor; selectively binds PKA-RI with high affinity and blocks its interaction with AKAP; cell permeable | ||
| 6760 | Raphin 1 | Mar 2019 |
| Inhibitor of the regulatory subunit PPP1R15B of protein phosphatase 1; orally bioavailable and brain penetrant | ||
| 6867 | Rhein | Apr 2019 |
| FTO (mRNA N6-methyladenine demethylase) inhibitor; also inhibits ALKBH2 and ALKBH3 | ||
| 6708 | SAH-EZH2 | May 2019 |
| EZH2/EDD interaction inhibitor; suppresses PCR2 complex function | ||
| 6881 | SB 4 | May 2019 |
| Potent BMP4 agonist | ||
| 6488 | 5(6)-SFX (Fluorescein), SE | Dec 2018 |
| Green fluorescent dye for the labeling of primary amines | ||
| 6245 | SM 16 | Jan 2019 |
| Potent TGF-βRI inhibitor; orally bioavailable | ||
| 6597 | SPRi 3 | Feb 2019 |
| Potent sepiapterin reductase (SPR) inhibitor; attenuates proliferation of CD4+ T cells | ||
| 6566 | STAD 2 | Feb 2019 |
| AKAP disruptor; selectively binds PKA-RII and blocks its interaction with AKAP; cell permeable | ||
| 6815 | Selumetinib | May 2019 |
| Potent and selective MEK inhibitor; orally bioavailable | ||
| 6829 | (R)-Shikonin | May 2019 |
| PTEN inhibitor; induces necroptosis; anti-inflammatory | ||
| 6740 | Siramesine hydrochloride | Apr 2019 |
| High affinity σ agonist (σ2 > σ1) | ||
| 6816 | Sitagliptin phosphate | Feb 2019 |
| Potent and selective DPP IV inhibitor | ||
| 6814 | Sorafenib | Apr 2019 |
| Potent Raf-1 inhibitor; also inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and cKIT | ||
| 6575 | StRIP16 | Apr 2019 |
| Rab8a GTPase-binding stapled peptide | ||
| 6634 | Surfen | Apr 2019 |
| Heparin sulfate antagonist | ||
| 6726 | T-peptide | Jan 2019 |
| Cytotoxic Tau peptide; cell permeable | ||
| 6587 | TAK 242 | Dec 2018 |
| TLR4 signaling inhibitor | ||
| 6777 | TAK 375 | Jan 2019 |
| Very high affinity and selective melatonin receptor agonist | ||
| 6621 | TFAX 488, TFP | Jan 2019 |
| Green fluorescent dye; amine reactive | ||
| 6624 | TFAX 568, SE | Dec 2018 |
| Orange fluorescent dye; amine reactive | ||
| 6625 | TFAX 594, SE | Dec 2018 |
| Red fluorescent dye; amine reactive | ||
| 6749 | TH 5487 | Apr 2019 |
| Selective 8-oxoguanine DNA glycosylase 1 (OGG1) inhibitor | ||
| 6334 | THDOC | Jan 2019 |
| Positive modulator of GABAA receptors; endogenous neurosteroid | ||
| 6746 | TL 13-110 | Apr 2019 |
| Negative control for TL 13-112 | ||
| 6745 | TL 13-112 | Apr 2019 |
| Selective ALK Degrader | ||
| 6744 | TL 13-12 | Apr 2019 |
| Selective ALK degrader | ||
| 6747 | TL 13-22 | Apr 2019 |
| Negative control for TL 13-12 | ||
| 3719 | Talabostat mesylate | Feb 2019 |
| Potent DPP IV inhibitor; activates NLRP1b inflammasome | ||
| 6266 | Taxol Janelia Fluor® 646 | Feb 2019 |
| Red fluorescent taxol derivative | ||
| 6949 | Thalidomide - linker 10 | May 2019 |
| Thalidomide-alkylC2-amine | ||
| 6951 | Thalidomide - linker 12 | May 2019 |
| Thalidomide-PEG5-ethylamine | ||
| 6686 | Thalidomide - linker 5 | Jan 2019 |
| Thalidomide-PEG2-alkyne | ||
| 6850 | Thalidomide - linker 6 | Mar 2019 |
| Thalidomide-AlkylC2-Amine | ||
| 6685 | Thalidomide, propargyl | Jan 2019 |
| Alkyne-functionalized Thalidomide; 'click' cereblon ligand for PROTACs | ||
| 6864 | Ticagrelor | Apr 2019 |
| High affinity and reversible P2Y12 antagonist; displays inverse agonism in vitro; also inhibits ENT1 | ||
| 6762 | Urolithin A | Apr 2019 |
| PI 3-K/Akt/mTOR signaling inhibitor; blocks phosphorylation of Akt and p70S6K in vitro | ||
| 6654 | VAS 2870 | Dec 2018 |
| NADPH oxidase (Nox) inhibitor | ||
| 6880 | VH 032 - linker 10 | Apr 2019 |
| VH 032-alkylC10-amine | ||
| 6890 | VH 032 - linker 11 | Apr 2019 |
| VH 032-AlkylC8-Amine | ||
| 6907 | VH 032 - linker 12 | Apr 2019 |
| VH 032-PEG2-amine | ||
| 6679 | VH 032 - linker 4 | Apr 2019 |
| VH 032-PEG3-CH2CH2COOH | ||
| 6680 | VH 032 - linker 5 | Jan 2019 |
| VH 032-alkylC4-terminal carboxylic acid | ||
| 6684 | VH 032 - linker 6 | Jan 2019 |
| VH 032-PEG2-alkyne | ||
| 6852 | VH 032 - linker 7 | Apr 2019 |
| VH 032-AlkylC2-Amine | ||
| 6853 | VH 032 - linker 8 | Apr 2019 |
| VH 032-AlkylC6-Amine | ||
| 6879 | VH 032 - linker 9 | Apr 2019 |
| VH 032-PEG1-amine | ||
| 6683 | VH 032, propargyl | Jan 2019 |
| Alkyne-functionalized VH 032; 'click' VHL ligand for PROTACs | ||
| 6355 | VU 0650991 | Apr 2019 |
| Non-competitive GLP-1 antagonist; orally bioavailable and brain penetrant | ||
| 6692 | WM 1119 | Mar 2019 |
| High affinity KAT6A (MOZ) competitive inhibitor | ||
| 6719 | YH 239-EE | Feb 2019 |
| Promotes survival of muscle stem cells (MuSCs); MDM2 inhibitor; activates p53 activity | ||
| 6351 | (R)-ZINC 3573 | Jan 2019 |
| MRGPRX2 agonist | ||
| 6352 | (S)-ZINC 3573 | Jan 2019 |
| Negative control for (R)-ZINC 3573 | ||
| 6606 | dBRD9 | Jan 2019 |
| Potent and selective BRD9 degrading PROTAC | ||
| 6605 | dTAG-13 | Mar 2019 |
| Degrades mutant FKBPF36V fusion proteins; useful alternative to genetic methods for target validation | ||
| 6607 | dTRIM 24 | Jan 2019 |
| TRIM24 degrading PROTAC | ||
| 5497 | ent-LP 99 | Dec 2018 |
| Negative Control for LP 99 | ||
| 6659 | sBADA | Feb 2019 |
| Green fluorescent D-amino acid for labeling peptidoglycans in bacteria | ||
| 6865 | uPSEM 792 hydrochloride | Apr 2019 |
| Highly potent PSAM4-GlyR and PSAM4-5-HT3 chimeric ion channel agonist; brain-penetrant | ||
| 6866 | uPSEM 817 tartrate | Mar 2019 |
| Highly potent and selective uPSAM4-GlyR and PSAM4-5-HT3 chimeric ion channel agonist; brain-penetrant |